Activating p53 and Inhibiting Superenhancers to Cure Leukemia.
Overview
abstract
In a recent study, Minzel and colleagues identified a novel series of molecules that inhibit casein kinase 1α (CK1α), CDK7, and CDK9, resulting in p53 activation and preferential inhibition of superenhancer (SE)-driven transcription. This study demonstrates a highly effective therapeutic strategy combining p53 activation with suppression of SEs to promote the cooperative killing of leukemic cells.
